5 Analysts Have This To Say About Pactiv Evergreen
Portfolio Pulse from Benzinga Insights
In the last three months, 5 analysts have updated their ratings on Pactiv Evergreen (NASDAQ:PTVE), with a shift towards a more neutral stance in the last 30 days. The average 12-month price target for PTVE has been raised to $16.3, indicating a 39.67% increase from the previous target of $11.67. Analysts from Goldman Sachs, Jefferies, UBS, Citigroup, and B of A Securities have adjusted their ratings and price targets, reflecting changes in market dynamics and company performance. Despite facing revenue challenges with a -14.29% growth over 3 months, PTVE shows strong financial health with a net margin of 2.1%, an ROE of 2.25%, and an ROA of 0.44%, outperforming industry benchmarks.
February 13, 2024 | 5:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Pactiv Evergreen's ratings have been updated by 5 analysts, showing a more neutral stance recently. The average 12-month price target has increased to $16.3, suggesting a potential upside. Despite revenue decline, the company's financial health remains strong with high net margin, ROE, and ROA.
The increase in the average price target to $16.3 reflects a positive outlook from analysts, suggesting a potential upside for PTVE's stock price in the short term. The company's strong financial health indicators, such as net margin, ROE, and ROA, despite a revenue decline, support a positive impact on the stock price. The recent neutral stance by analysts indicates a cautious optimism, which could lead to increased investor interest.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100